Welcome to our dedicated page for Recursion Pharmaceuticals SEC filings (Ticker: RXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Recursion Pharmaceuticals, Inc. filings document the regulatory record for a clinical-stage TechBio company advancing investigational medicines through an AI-native discovery and development platform. Its 8-K reports disclose operating results, financial condition, Regulation FD presentations, clinical and pipeline updates, partner milestones and material corporate events.
Proxy materials cover annual-meeting matters, director elections, executive compensation and governance practices. Other filings include leadership-transition disclosures, shelf-registration and prospectus-supplement records for Class A common stock, and capital-structure disclosures tied to shares issued under the Tempus master agreement.
A holder of Class A shares has filed a notice to sell 40,000 shares through Fidelity Brokerage Services LLC on the NASDAQ, with an aggregate market value of $164,800.00. The shares were originally acquired on 09/01/2016 as founders’ shares from the issuer as compensation.
Over the prior three months, the same seller, identified as Christopher C. Gibson, reported six separate sales of 40,000 Class A shares each, between 11/04/2025 and 01/20/2026, at disclosed gross proceeds ranging from $166,400.00 to $208,400.00. By signing, the seller represents they do not know of undisclosed material adverse information about the issuer.
Recursion Pharmaceuticals, Inc. shareholder ARK Investment Management LLC and its founder Catherine D. Wood have updated their ownership disclosure. They report beneficial ownership of 37,316,856 shares of Class A common stock, representing 7.25% of the class as of the event date.
ARK has sole voting power over 35,278,842 shares and shared voting power over 592,161 shares, with sole dispositive power over all 37,316,856 shares. Catherine D. Wood reports shared voting power over 35,871,003 shares and shared dispositive power over 37,316,856 shares. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Recursion.
This Form 144 notice shows Blake C. Borgeson planning to sell up to 220,000 shares of the issuer’s Class A stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $924,000.
The filing also describes how these securities were acquired as founder shares from the issuer in two compensation grants of 110,000 Class A shares each on 09/01/2016 and 09/01/2017.
Over the past three months, Borgeson has already sold 220,000 Class A shares on 12/02/2025 for gross proceeds of $961,400 and another 220,000 shares on 01/06/2026 for $959,200.
Recursion Pharmaceuticals director Christopher Gibson reported a planned share sale and related conversion. On January 20, 2026, he converted 40,000 shares of Class B Common Stock into 40,000 shares of Class A Common Stock at $0 per share pursuant to the Class B conversion feature. The same day, he sold 40,000 Class A shares at $4.47 per share under a Rule 10b5-1 trading plan adopted on May 12, 2025.
After these transactions, Gibson directly owned 913,839 shares of Class A Common Stock. He also reported additional indirect Class A holdings through entities he manages or serves as trustee, including 386,000 shares via LAHWRAN-3 LLC, 388,000 shares via LAHWRAN-4 LLC, and 50,000 shares via the Gibson Family Trust, as well as multiple outstanding stock options with various exercise prices and expirations.
Christopher C. Gibson has filed a Rule 144 notice to sell 40,000 shares of Class A stock through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate aggregate market value of $178,800 and an expected sale date of 01/20/2026. The filing reports that these 40,000 shares were acquired on 09/01/2016 as founders shares from the issuer as compensation. The notice lists 514,895,802 shares of this class outstanding. Over the prior three months, Gibson reported multiple sales of Class A shares, including 100,000 shares on 10/23/2025 for gross proceeds of $570,000 and separate 40,000‑share transactions on 11/04/2025, 11/19/2025, 12/04/2025, 12/19/2025, and 01/05/2026, with individual gross proceeds ranging from $166,400 to $208,400.
Recursion Pharmaceuticals, Inc. furnished an updated investor presentation dated January 12, 2026. The presentation will be used at the JP Morgan Healthcare Conference and in other investor meetings, giving an overview of the company and its strategy. It is attached as Exhibit 99.1 to this report and is provided under Regulation FD, meaning it is being shared to keep all investors equally informed. The materials are expressly treated as "furnished" rather than "filed," which limits their exposure to certain Exchange Act liabilities and affects how they may be incorporated by reference into other regulatory documents.
Recursion Pharmaceuticals’ CSO David Hallett filed a Form 3 disclosing his initial beneficial ownership in the company’s Class A common stock and equity awards as of 01/01/2026. He directly holds 287,928 shares of Class A common stock, plus restricted stock units (RSUs) covering 277,759 and 28,454 shares. These RSUs vest in equal quarterly installments from February 15, 2025 through November 15, 2028, and from May 15, 2025 through February 15, 2029, contingent on continued service.
Hallett also holds multiple stock options on Class A common shares, including options for 70,037 shares at $7.25 and 740,686 shares at $6.09, each vesting monthly after initial vesting dates in 2025. Additional options with a $0.01 exercise price cover tranches such as 56,531, 75,375, 80,510, 9,241, and 150,888 shares, with some already fully exercisable and others vesting quarterly through dates extending to March 15, 2028, including awards assumed in the acquisition of Exscientia plc.
Recursion Pharmaceuticals director Blake Borgeson reported selling 220,000 shares of the company’s Class A common stock on January 6, 2026 at a price of $4.36 per share. After this transaction, he beneficially owned 6,649,863 shares of Class A common stock in direct ownership.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that Borgeson adopted on August 31, 2025. Such plans are designed to allow insiders to sell shares according to a preset schedule or conditions, helping separate routine liquidity transactions from day-to-day market or company developments.
Recursion Pharmaceuticals director Christopher Gibson reported several share moves on January 5, 2026. He converted 60,000 shares of Class B Common Stock into 60,000 shares of Class A Common Stock at a stated price of $0, then sold 40,000 Class A shares at $4.25 per share and made a gift of 20,000 Class A shares. After these transactions, he directly held 913,839 shares of Class A Common Stock.
The filing also shows he directly holds 4,663,334 shares of Class B Common Stock, each convertible into one Class A share, and additional Class B holdings through LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust. Multiple stock options to buy Class A shares remain outstanding with exercise prices ranging from $2.48 to $11.40 and expirations between 2030 and 2035. The conversion, sale, and gift were made under a Rule 10b5-1 trading plan adopted on May 12, 2025.
Recursion Pharmaceuticals director Dean Y. Li received a new equity grant. On 01/02/2026, he was awarded 2,381 shares of Class A Common Stock at a price of $0. The filing states these shares were issued under the company’s Outside Director Compensation Policy, meaning they represent routine board compensation rather than an open-market purchase. After this grant, Li directly beneficially owned 1,240,909 Class A shares, in addition to indirect holdings through the Dean Y. Li Revocable Trust, the Dean Y. Li GRAT, and the Dean Y. Li 2021 Family Trust.